Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for glatiramer acetate prefilled syringes

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 306 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glatirameracetat in der Darreichungsform Fertigspritze (ATC-Code nach WHO: L03AX13)

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

Structured data marks electronic submission as not allowed, while the notice text says communication and transmission o...

The notice references project-space documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfri...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive rebate agreements under § 130a(8) SGB V for glatiramer acetate in prefilled syringes.
  • Open-house model with participation open to all eligible pharmaceutical companies during the participation period.
Afficher le résumé complet

Open-house procurement for non-exclusive pharmaceutical rebate agreements on glatiramer acetate prefilled syringes (ATC L03AX13) in Germany. The contract is a supplies framework-type arrangement with unlimited participation during the participation period, no individual negotiations, no exclusivity, and unknown call-off volume. Participation is electronic via DTVP project space, but submission is marked as not allowed in the structured data, which appears inconsistent with the document text and should be clarified. No detailed procurement document text beyond the TED XML notice was provided, so document-based requirements may be incomplete.

Risques

Structured data marks electronic submission as not allowed, while the notice text says communication and transmission o...

The notice references project-space documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfri...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical entrepreneur for the offered medicines under German medicines law, as stated in the notice.

Eligibility

  • Submission of the completed self-declaration on the absence of exclusion grounds under §§ 123, 124 GWB.

Administrative

  • Submission of the Russia sanctions self-declaration for the bidder and any involved company.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for glatiramer acetate prefilled syringes

Open-house lot for non-exclusive rebate agreements for the pharmaceutical product glatiramer acetate in prefilled syringe form. Scope is supplies of medicinal products in Germany, with participation open to all interested pharmaceutical companies that meet and accept the stated conditions. No exclusivity or guaranteed minimum purchase volume is provided.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 30, 2027

Détails de la procédure

Date de publication
17 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
256358-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30